Floxuridine
 | This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2009) |
| File:Floxuridine.png | |
| Systematic (IUPAC) name | |
|---|---|
|
5-Fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione | |
| Identifiers | |
| CAS Number | 50-91-9 |
| ATC code | none |
| PubChem | CID 5790 |
| DrugBank | APRD00692 |
| Chemical data | |
| Formula | C9H11FN2O5 |
| Molar mass | 246.192 g/mol[[Script error: No such module "String".]] |
| (verify) | |
Floxuridine is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer.
Pharmacology
Floxuridine, an analog of 5-fluorouracil, is a fluorinated pyrimidine.
Mechanism of action
Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.
History
Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to F H Faulding, which became Mayne Pharma.
Suppliers
In the US the drug is supplied by APP Pharmaceuticals, LLC; Hospira, Inc.; and Bedford Laboratories.
- Pages with script errors
- Articles lacking sources from December 2009
- Articles with invalid date parameter in template
- All articles lacking sources
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- 2Fix
- Chemotherapeutic agents
- Nucleosides
- Organofluorides
- Pyrimidones
